Abnormal amphiregulin expression correlates with gastric cancer prognosis

Oncotarget

Volumn 7, Issue 47, 2016, Pages 76684-76692

  Wang, Bing ^a   Yong, Hongmei ^b   Zhu, Huijun ^c   Ni, Daguang ^a   Tang, Sijie ^a   Zhang, Shu ^c   Wang, Wei ^c   Zhou, Yan ^a   Zhao, Wei ^d   Ding, Guipeng ^d   Zhu, Jin ^e   Li, Xiaohua ^a,f,g   Feng, Zhenqing ^a,d  

^a Zhangjiagang Aoyang Hospital   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

^c NANTONG UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

^e Huadong Medical Institute of Biotechniques   (China)

^f JIANGSU UNIVERSITY   (China)

^g THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Amphiregulin; Gastric cancer; Prognosis

Indexed keywords

AMPHIREGULIN; MESSENGER RNA; TUMOR MARKER;

ADULT; ARTICLE; BIOINFORMATICS; CANCER PROGNOSIS; CANCER STAGING; CELL DEDIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISTANT METASTASIS; FEMALE; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; TISSUE MICROARRAY; TUMOR INVASION; AGED; CANCER GRADING; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; SURVIVAL ANALYSIS;

ADULT; AGED; AMPHIREGULIN; BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84998953618     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12436     Document Type: Article

References (44)

1. Loffeld RJ, Willems I, Flendrig JA, Arends JW. Helicobacter pylori and gastric carcinoma. Histopathology. 1990; 17:537-41.
2. Recavarren-Arce S, Leon-Barua R, Cok J, Berendson R, Gilman RH, Ramirez-Ramos A, Rodriguez C, Spira WM. Helicobacter pylori and progressive gastric pathology that predisposes to gastric cancer. Scand J Gastroenterol. 1991; 181:51-7.
3. Arnold M, Moore SP, Hassler S, Ellison-Loschmann L, Forman D, Bray F. The burden of stomach cancer in indigenous populations: a systematic review and global assessment. Gut. 2014; 63:64-71.
4. Chun, N. Ford JM. Genetic testing by cancer site: stomach. Cancer J. 2012; 18:355-63.
5. Kanda, M. Kodera Y. Recent advances in the molecular diagnostics of gastric cancer. World J Gastroenterol. 2015; 21:9838-52.
6. Yang L, Wang J, Li J, Zhang H, Guo S, Yan M, Zhu Z, Lan B, Ding Y, Xu M, Li W, Gu X, Qi C, et al. Identification of serum biomarkers for gastric cancer diagnosis using a human proteome microarray. Mol Cell Proteomics. 2015.
7. Kalnina Z, Meistere I, Kikuste I, Tolmanis I, Zayakin P, Line A. Emerging blood-based biomarkers for detection of gastric cancer. World J Gastroenterol. 2015; 21:11636-53.
8. Berasain C, Avila MA. Amphiregulin. Semin Cell Dev Biol. 2014; 28:31-41.
9. Stoll SW, Stuart PE, Lambert S, Gandarillas A, Rittie L, Johnston A, Elder JT. Membrane-Tethered Intracellular Domain of Amphiregulin Promotes Keratinocyte Proliferation. J Invest Dermatol. 2016; 136:444-52.
10. Nojiri T, Yoshizato T, Fukami T, Obama H, Yagi H, Yotsumoto F, Miyamoto S. Clinical significance of amphiregulin and epidermal growth factor in colostrum. Arch Gynecol Obstet. 2012; 286:643-7.
11. Katoh Y, Katoh M. Canonical WNT signaling pathway and human AREG. Int J Mol Med. 2006; 17:1163-6.
12. Kneissl J, Keller S, Lorber T, Heindl S, Keller G, Drexler I, Hapfelmeier A, Hofler H, Luber B. Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines. Int J Oncol. 2012; 41:733-44.
13. Yoshida M, Shimura T, Fukuda S, Mizoshita T, Tanida S, Kataoka H, Kamiya T, Nakazawa T, Higashiyama S, Joh T. Nuclear translocation of pro-amphiregulin induces chemoresistance in gastric cancer. Cancer Sci. 2012; 103:708-15.
14. Saeki T, Salomon D, Normanno N, Johnson G, Gullick W, Mandai K, Moriwaki S, Takashima S, Kuniyasu M, Tahara E, Kawami H, Nishiyama M, Toge T. Immunohistochemical detection of cripto-1, amphiregulin and transforming growth-factor-alpha in human gastric carcinomas and intestinal metaplasias. Int J Oncol. 1994; 5:215-23.
15. Akagi M, Yokozaki H, Kitadai Y, Ito R, Yasui W, Haruma K, Kajiyama G, Tahara E. Expression of amphiregulin in human gastric cancer cell lines. Cancer. 1995; 75:1460-6.
16. Bai J, Yong HM, Chen FF, Mei PJ, Liu H, Li C, Pan ZQ, Wu YP, Zheng JN. Cullin1 is a novel marker of poor prognosis and a potential therapeutic target in human breast cancer. Ann Oncol. 2013; 24:2016-22.
17. Bai J, Zhou Y, Chen G, Zeng J, Ding J, Tan Y, Zhou J, Li G. Overexpression of Cullin1 is associated with poor prognosis of patients with gastric cancer. Hum Pathol. 2011; 42:375-83.
18. Huang H, Wu J, Jin G, Zhang H, Ding Y, Hua Z, Zhou Y, Xue Y, Lu Y, Hu Z, Xu Y, Shen H. A 5'-flanking region polymorphism in toll-like receptor 4 is associated with gastric cancer in a Chinese population. J Biomed Res. 2010; 24:100-6.
19. Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev. 2015; 20:25-40.
20. Sue S, Shibata W, Maeda S. Helicobacter pylori-Induced Signaling Pathways Contribute to Intestinal Metaplasia and Gastric Carcinogenesis. Biomed Res Int. 2015; 2015:737621.
21. Stoll SW, Stuart PE, Swindell WR, Tsoi LC, Li B, Gandarillas A, Lambert S, Johnston A, Nair RP, Elder JT. The EGF receptor ligand amphiregulin controls cell division via FoxM1. Oncogene. 2016; 35:2075-86.
22. Cook PW, Pittelkow MR, Keeble WW, Graves-Deal R, Coffey RJ Jr., Shipley GD. Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. Cancer Res. 1992; 52:3224-7.
23. Kitadai Y, Yasui W, Yokozaki H, Kuniyasu H, Ayhan A, Haruma K, Kajiyama G, Johnson GR, Tahara E. Expression of amphiregulin, a novel gene of the epidermal growth factor family, in human gastric carcinomas. Jpn J Cancer Res. 1993; 84:879-84.
24. Fang L, Yu Y, Zhang R, He J, Sun YP. Amphiregulin mediates hCG-induced StAR expression and progesterone production in human granulosa cells. Sci Rep. 2016; 6:24917.
25. Mihi B, Van Meulder F, Rinaldi M, Van Coppernolle S, Chiers K, Van den Broeck W, Goddeeris B, Vercruysse J, Claerebout E, Geldhof P. Analysis of cell hyperplasia and parietal cell dysfunction induced by Ostertagia ostertagi infection. Vet Res. 2013; 44: p. 121.
26. Nagathihalli NS, Beesetty Y, Lee W, Washington MK, Chen X, Lockhart AC, Merchant NB. Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-alpha: impact on gastrointestinal cancers driven by secondary bile acids. Cancer Res. 2014; 74:2062-72.
27. Schumacher Y, Aparicio T, Ourabah S, Baraille F, Martin A, Wind P, Dentin R, Postic C, Guilmeau S. Dysregulated CRTC1 activity is a novel component of PGE2 signaling that contributes to colon cancer growth. Oncogene. 2016; 35:2602-14.
28. Yotsumoto F, Yagi H, Suzuki SO, Oki E, Tsujioka H, Hachisuga T, Sonoda K, Kawarabayashi T, Mekada E, Miyamoto S. Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun. 2008; 365:555-61.
29. Willmarth NE, Ethier SP. Amphiregulin as a novel target for breast cancer therapy. J Mammary Gland Biol Neoplasia. 2008; 13:171-9.
30. Kim JW, Kim DK, Min A, Lee KH, Nam HJ, Kim JH, Kim JS, Kim TY, Im SA, Park IA. Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer. J Cancer Res Clin Oncol. 2015.
31. Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev IS, Tacheuchi S, Mouri H, Yamashita K, Ohtsubo K, Yano S. The EGFR ligands amphiregulin and heparinbinding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. Clin Cancer Res. 2011; 17:3619-30.
32. Stoll SW, Stuart PE, Swindell WR, Tsoi LC, Li B, Gandarillas A, Lambert S, Johnston A, Nair RP, Elder JT. The EGF receptor ligand amphiregulin controls cell division via FoxM1. Oncogene. 2015.
33. Eckstein N, Servan K, Girard L, Cai D, von Jonquieres G, Jaehde U, Kassack MU, Gazdar AF, Minna JD, Royer HD. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem. 2008; 283:739-50.
34. Edgar KA, Crocker L, Cheng E, Wagle MC, Wongchenko M, Yan Y, Wilson TR, Dompe N, Neve RM, Belvin M, Sampath D, Friedman LS, Wallin JJ. Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition. Genes Cancer. 2014; 5:113-26. doi: 10.18632/genesandcancer.10.
35. Roskoski R, Jr., The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014; 79:34-74.
36. Ichikawa W, Terashima M, Ochiai A, Kitada K, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H, Sasako M. Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer. Gastric Cancer. 2016.
37. Pan Y, Sun C, Huang M, Liu Y, Qi F, Liu L, Wen J, Liu J, Xie K, Ma H, Hu Z, Shen H. A genetic variant in pseudogene E2F3P1 contributes to prognosis of hepatocellular carcinoma. J Biomed Res. 2014; 28:194-200.
38. Meng WCS, Pan Y, Zhao X. Epirubicin-gold nanoparticles suppress hepatocellular carcinoma xenograft growth in nude mice. J Biomed Res. 2015; 29:486-490.
39. Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta. 2011; 1816:119-31.
40. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995; 48:876-8.
41. Li X, Kaplun A, Lonardo F, Heath E, Sarkar FH, Irish J, Sakr W, Sheng S. Trop2 is overexpressed in gastric cancer and predicts poor prognosis. Oncotarget. 2016; 7:6136-45. doi: 10.18632/oncotarget.6733.
42. Zhao W, Zhu HJ, Zhang S, Yong HM, Wang W, Zhou Y, Wang B, Wen JB, Qiu ZN, Ding GP, Feng ZQ, Zhu J. Expression and prognostic significance of the alpha B-crystallin gene in human hepatocellular carcinoma. Hum Pathol. 2009; 40:300-5.
43. Tang Q, Liu YF, Zhu XJ, Li YH, Zhu J, Zhang JP, Feng ZQ, Guan XH. HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells. Mol Cancer Res. 2011; 9:733-45.
44. Zhai X, Zhu H, Wang W, Zhang S, Zhang Y, Mao G. Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC. Med Oncol. 2014; 31: p. 970.